Both the binding test and biodistribution investigation yielded further data supporting the favorable and specific binding of NIR760-XLP6 (20) to CB2R. Significantly, the measured tumor-to-normal (T/N) ratio reached a maximum value of 7.9 in the DBT-CB2 tumor at 72 h after intravenous administration. This evidence concerns the gene CNR2 and neoplasm.